VETERINARY TEAM REFERENCE

DEA & state schedules

Scheduling applies to the medication, not to the patient. This independent reference is not affiliated with the DEA.

Fluoxetine

FEDERAL STATUS

Not federally scheduled

The identified ingredients in this entry are not listed in the reviewed federal schedules. Prescription-only status, product restrictions and state law are separate questions.

Federal source ↗

State / prescribing or dispensing jurisdiction

STATE STATUS

Select a jurisdiction

Choose the state relevant to prescribing or dispensing. Patient residence alone may not determine every applicable rule.

What each federal schedule means

Highlighted rows match the verified federal or selected state schedule. The schedule describes legal control and abuse potential; it does not rank clinical usefulness or establish a dose.

Federal Schedules I–V: meaning and practice implications
Schedule	Meaning and practice
I	High abuse potential; no currently accepted medical use in U.S. treatment; lacks accepted safety under medical supervision. In practice: Not available for routine veterinary prescribing. Authorized research is a separate pathway.
II	High abuse potential; accepted medical use, sometimes with severe restrictions; abuse can cause severe dependence. In practice: No prescription refills under federal law. Strict prescribing, security and record requirements apply.
III	Less abuse potential than I or II; accepted medical use; abuse can cause moderate or low physical dependence or high psychological dependence. In practice: Federal prescriptions allow up to five authorized refills within six months. State rules may be stricter.
IV	Lower abuse potential than III; accepted medical use; limited dependence risk relative to III. In practice: The same federal five-refill / six-month prescription limit applies. Controlled-drug handling still applies.
V	Lower abuse potential than IV; accepted medical use; limited dependence risk relative to IV. In practice: Still controlled. Check authorized refills and state limits; do not automatically apply the III–IV refill rule.

What this means for the chart

For a controlled medication, confirm the prescriber’s authority for the applicable schedule, the exact formulation and quantity, authorized refills, secure handling, and required inventory / dispensing records. Check the state’s veterinary rules and any prescription monitoring program (PDMP) requirements or exemptions.

A PDMP reporting requirement does not by itself make a drug scheduled. “Not federally scheduled” does not mean over the counter, risk-free, or exempt from state law. States may use additional categories, such as Schedule VI, outside the federal I–V system.

← Medication & Supplement Reference

VETERINARY TEAM REFERENCE · MEDICATION

Fluoxetine

A selective serotonin reuptake inhibitor used in behavioral treatment. Reconcile is labeled for canine separation anxiety together with a behavior modification plan.

Selective serotonin reuptake inhibitorProduct-specific clinical reference

Updated October 16, 2026 · Sources and review status below

For veterinarians and veterinary staff. Product-label information is distinct from extra-label clinical practice. This is not a complete prescribing formulary or an automated interaction screen. Verify the current label, exact formulation, patient and species-specific clinical reference before use. Independent veterinary/pharmacy review remains pending.

Prescribing overview

Reconcile supports a structured behavior-modification plan for canine separation anxiety. It is not a sedative or a labeled treatment for aggression.

Key prescribing checks

The Reconcile label contraindicates use in dogs with epilepsy or a seizure history. Review other drugs that lower the seizure threshold.
Medication reconciliation must include monoamine oxidase inhibitors and other serotonergic drugs. Label-specific separation periods matter when changing treatment.
Appetite reduction, lethargy and behavioral changes require follow-up; medication is one part of a monitored behavior plan.

Uses by species

Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.

Dogs

FDA-approved Reconcile indication

Separation anxiety with behavior modification

Other behavioral disorders have not been clinically tested in this label.

Use / indication source ↗

Pharmacology & pharmacokinetics

Mechanism and clinical role

Inhibits presynaptic serotonin reuptake; active norfluoxetine also contributes.

Absorption, distribution, metabolism and elimination

Dog single-dose data: fluoxetine half-life 6.2 hours; norfluoxetine 49 hours. Hepatic CYP metabolism produces norfluoxetine.

SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC

Contraindications & cautions

Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.

Reconcile

U.S. canine oral chewable label.

Contraindications · when not to use

Epilepsy/seizure history; fluoxetine or other SSRI hypersensitivity.
Do not combine with seizure-threshold-lowering drugs or MAO inhibitors; observe label washouts.

Precautions & monitoring

Not recommended for aggression; reproductive and young-patient safety studies are lacking.

Safety sources checked: October 16, 2026. Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.

Adverse effects

Appetite reduction, lethargy and seizures may occur.

These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.

Dosing & administration

Verify the source before prescribing. The regimens below summarize selected veterinary product labels, not every accepted veterinary use. They are not automatic substitutions between brands or formulations. Renal/hepatic disease, concurrent therapy, age, indication and clinical response can require a different plan.

Selected product-label regimens — not a patient-specific prescription
Species & indication	Labeled regimen	Eligibility & source
Dogs ≥6 months and ≥4 kg (8.8 lb)Separation anxietyReconcile chewable tablets	1–2 mg/kg (0.5–0.9 mg/lb) Oral · Once daily Reevaluate absent improvement by 8 weeks; longer clinical safety/effectiveness unestablished	With/without food; concurrent behavior modification required. Verify full dosing label ↗

Observe ≥14 days after MAOIs and 6 weeks after stopping before adversely interacting drugs.

Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗

Drug & supplement interactions

This is a selected interaction reference, not an automated or comprehensive combination checker. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.

Reconcile

U.S. canine oral chewable label.

MAOI separation: at least 14 days before Reconcile; allow six weeks after Reconcile before potentially interacting drugs. Review CYP450-active medicines and TCAs.

Interaction source ↗

Monitoring

Track appetite, behavior and treatment response; contraindicated with seizure history.

Client counseling

Do not double missed doses; continue training.

This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.

Storage & handling

20–25°C; retain desiccant and close bottle completely.

Brands, formulations & ingredient identity

Active ingredients

Fluoxetine

Other searchable names: fluoxetine hydrochloride

Reconcile identifies a flavored veterinary chewable containing fluoxetine hydrochloride; the salt name and fluoxetine describe the same active-drug relationship.

A matching ingredient name does not establish equivalent formulation, concentration, approval or dispensing instructions.

Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.

Reconcile

Formulation: Oral chewable tablet
Label / product scope: Dogs

Veterinary product; labeled treatment includes behavior modification.

Product label / source ↗

References & review status

Clinical reference updated October 16, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.

01DailyMed: Reconcile prescribing information ↗

Search another medication or supplement →

Prescribing overview

Key prescribing checks

Uses by species

Dogs

Pharmacology & pharmacokinetics

Mechanism and clinical role

Absorption, distribution, metabolism and elimination

Contraindications & cautions

Contraindications · when not to use

Precautions & monitoring

Adverse effects

Dosing & administration

Drug & supplement interactions

Reconcile

Monitoring

Client counseling

Storage & handling

Brands, formulations & ingredient identity

Active ingredients

Reconcile

References & review status

Related Resources